Empiric Management of Posterior Cervical Lymphadenitis and Flegmon
Diagnostic Indicators for Initiating Antibiotics
- The presence of a deep soft‑tissue inflammation (flegmon) warrants empiric antimicrobial therapy covering Staphylococcus aureus (including community‑acquired MRSA) and group A β‑hemolytic streptococci. 1, 2
- Involvement of multiple anatomic sites (e.g., two separate lesions) also signals the need for systemic antibiotics. 1, 2
Recommended Oral Empiric Regimens (First‑Line Dual Coverage)
- Clindamycin 300–450 mg orally three times daily provides single‑agent coverage for both MRSA and streptococci. 1, 2, 3, 4
- Trimethoprim‑sulfamethoxazole (double‑strength) 160–800 mg twice daily + amoxicillin 500–875 mg twice daily offers combined MRSA and streptococcal activity. 1, 2, 3, 4
- Doxycycline 100 mg twice daily + amoxicillin 500–875 mg twice daily is an alternative dual‑coverage option. 1, 2, 3, 4
Duration of Therapy
Resistance‑Related Considerations
- Inducible clindamycin resistance can occur in MRSA strains that are erythromycin‑resistant; therefore, susceptibility testing is advisable. 3, 4, 7
- Local clindamycin resistance rates should be reviewed before using clindamycin as monotherapy. 2, 3
- If the clindamycin resistance prevalence exceeds 10 %, alternative agents (e.g., TMP‑SMX + amoxicillin or doxycycline + amoxicillin) should be selected. 2, 3
Indications for Obtaining Microbiologic Cultures
- Systemic manifestations such as fever or toxicity. 1, 2, 6
- Lack of satisfactory clinical improvement after initial oral therapy. 1, 2, 6
- Severe or extensive infection (e.g., rapidly spreading cellulitis). 1, 2, 6
Hospitalization and Intravenous Therapy Criteria
Hospital admission is recommended for patients with:
IV therapeutic options for admitted patients (dose per kilogram or standard adult dosing):